Suboxone: What is it?

by on June 22, 2015

Call 1 (888) 460-6556 to speak with a counselor.

(Source: CNN.com – Health)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Call 1 (888) 460-6556 to speak with a counselor.

Opioid drug Suboxone, designed for addiction treatment, is becoming more common on the street (Source: Health News: CBSNews.com)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

5 Ways We Can Reduce Drug Overdoses

June 17, 2015

Fatal drug overdose has reached epidemic levels in the U.S., surpassing vehicle-related deaths in 36 states, according to a new report from the Trust for America’s Health and Robert Wood Johnson Foundation. In a separate study, researchers found that drug overdoses in the United States tripled in the last 25 years. The two-fold tragedy of […]

Read the full article →

The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales

May 28, 2015

Conclusions Our analysis of the relative safety of buprenorphine and methadone for opioid substitution treatment reveals that buprenorphine is six times safer than methadone with regard to overdose risk among the general population. Clinicians should be aware of the increased risk of prescribing methadone, and tighter regulations are needed to prevent its diversion. (Source: BMJ […]

Read the full article →

Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States

May 20, 2015

Journal of Medical Economics, Ahead of Print. (Source: Journal of Medical Economics) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

A retrospective evaluation of inpatient transfer from high-dose methadone to buprenorphine substitution therapy

May 12, 2015

The product license of buprenorphine/naloxone for opioid substitution therapy indicates reducing methadone concentrations to 30 mg or less per day for a minimum of 1 week before transferring patients to buprenorphine and no sooner than 24 hours after the last methadone dose, because of the risk of precipitated withdrawal and a corresponding high risk of […]

Read the full article →

Factors associated with willingness to take extended release naltrexone among injection drug users.

May 2, 2015

CONCLUSIONS: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional […]

Read the full article →

Factors associated with willingness to take extended release naltrexone among injection drug users

May 2, 2015

Conclusions: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional […]

Read the full article →

Starting Suboxone Therapy in the ED Benefits Opioid-Dependent Patients (FREE)

April 28, 2015

By Daniel J. Pallin, MD, MPH Opioid-dependent individuals visiting the emergency department are much more likely to participate in addiction treatment when buprenorphine/naloxone therapy is started during the visit, a JAMA study finds.Investigators randomized some 330 adult patients reporting opioid dependence to one of … (Source: Physician’s First Watch current issue) MedWorm Sponsor Message: Directory […]

Read the full article →

Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients

April 20, 2015

The high prevalence of interrelated problems with opioid use disorder, injection drug use (IDU), and HIV/AIDS in Malaysia has led to the scale-up of public health approaches, including opioid agonist maintenance treatment with buprenorphine or methadone. Malaysia has more than 300,000 registered people who use drugs (PWUD)-approximately 1.1% of its population of about 30 million-and […]

Read the full article →